161 related articles for article (PubMed ID: 38105006)
21. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
[TBL] [Abstract][Full Text] [Related]
22. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
[TBL] [Abstract][Full Text] [Related]
23. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
24. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
[TBL] [Abstract][Full Text] [Related]
25. Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
Katsumata S; Shimokawa M; Hamada A; Haratake N; Nomura K; Fujino K; Yoshikawa M; Suzawa K; Shien K; Suda K; Ohara S; Fukuda S; Kinoshita F; Hayasaka K; Notsuda H; Takamori S; Muto S; Takanashi Y; Mizuno K; Kawase A; Hayakawa T; Sekihara K; Toda M; Matsuo S; Takegahara K; Hashimoto M; Nakahashi K; Endo M; Ozawa H; Fujikawa R; Tomioka Y; Namba K; Matsubara T; Suzuki J; Watanabe H; Takada K; Hoshino H; Kaiho T; Toyoda T; Kouki Y; Shiono S; Soh J; Ohde Y
Eur J Cancer; 2024 Apr; 201():113951. PubMed ID: 38417299
[TBL] [Abstract][Full Text] [Related]
26. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
27. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
29. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
[TBL] [Abstract][Full Text] [Related]
30. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and prognostic value of EGFR mutation in stage I lung adenocarcinoma with spread through air spaces after surgical resection.
Gao MG; Wang SZ; Han KH; Xie SN; Liu QY
Neoplasma; 2022 Dec; 69(6):1480-1489. PubMed ID: 36591802
[TBL] [Abstract][Full Text] [Related]
32. Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations.
Chen T; Wen J; Li Y; Deng J; Zhong Y; Hou L; She Y; Xie D; Chen C
Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38001033
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.
Hamada C; Tanaka F; Ohta M; Fujimura S; Kodama K; Imaizumi M; Wada H
J Clin Oncol; 2005 Aug; 23(22):4999-5006. PubMed ID: 16051951
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
[TBL] [Abstract][Full Text] [Related]
37. Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.
Deng Q; Wang F; Song L; Chen L; Huang Y; Guo Z; Yang H
Int J Med Sci; 2024; 21(4):765-774. PubMed ID: 38464823
[No Abstract] [Full Text] [Related]
38. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
39. Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation.
Hayasaka K; Takeda H; Sakurada A; Matsumura Y; Abe J; Shiono S; Notsuda H; Suzuki H; Endo M; Motohashi H; Okada Y
Clin Lung Cancer; 2024 Jan; 25(1):e43-e51. PubMed ID: 37985312
[TBL] [Abstract][Full Text] [Related]
40. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
